Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. 1999

H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
First Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, USA.

We examined the effect of troglitazone on immunoreactive endothelin-1 (ET-1) secretion from cultured bovine vascular endothelial cells (bVECs). Insulin (10(-9)-10(-7) M) stimulated ET-1 secretion in a dose-dependent fashion without any kinetic change. Troglitazone (1-20 microM) dose-dependently inhibited both spontaneous and insulin-stimulated ET-1 secretion. This inhibitory effect of troglitazone was associated with reduced ET-1 mRNA levels. Addition of indomethacin (100 microM) or Nw-nitro-l-arginine methyl ester (1 mM) and downregulation of protein kinase C by prolonged pretreatment of the cells with a phorbol ester, 12-O-tetradecanoylphorbol 13-acetate, did not affect the inhibitory effect of troglitazone at concentrations up to 10 microM. Troglitazone did not change the intracellular Ca2+ concentration stimulated by angiotensin II (10 microM). Other PPARgamma ligands, pioglitazone (1-10 microM) and 15-deoxy-delta 12, 14-prostaglandin J2 (1-10 microM), but not a PPARalpha ligand, bezafibrate (1-10 microM), dose-dependently suppressed spontaneous ET-1 secretion from bVECs. These results, taken together, suggest that troglitazone inhibits ET-1 mRNA expression and secretion in bVECs possibly through activation of PPARgamma. This inhibition may contribute to the hypotensive effect of troglitazone in insulin-resistant subjects.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D002417 Cattle Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor. Beef Cow,Bos grunniens,Bos indicus,Bos indicus Cattle,Bos taurus,Cow,Cow, Domestic,Dairy Cow,Holstein Cow,Indicine Cattle,Taurine Cattle,Taurus Cattle,Yak,Zebu,Beef Cows,Bos indicus Cattles,Cattle, Bos indicus,Cattle, Indicine,Cattle, Taurine,Cattle, Taurus,Cattles, Bos indicus,Cattles, Indicine,Cattles, Taurine,Cattles, Taurus,Cow, Beef,Cow, Dairy,Cow, Holstein,Cows,Dairy Cows,Domestic Cow,Domestic Cows,Indicine Cattles,Taurine Cattles,Taurus Cattles,Yaks,Zebus
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002839 Chromans Benzopyrans saturated in the 2 and 3 positions. Dihydrobenzopyrans
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D000077205 Pioglitazone A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS. Pioglitazone Hydrochloride,5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione,AD 4833,AD-4833,Actos,U 72107A,U-72107A,U72,107A,AD4833,U72107A
D000077288 Troglitazone A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. 5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione) - T,CS 045,CS-045,Prelay,Rezulin,CS045
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole

Related Publications

H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
January 1996, Life sciences,
H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
January 1991, Journal of cardiovascular pharmacology,
H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
February 1993, Diabetes,
H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
February 1990, Biochemical and biophysical research communications,
H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
July 1990, FEBS letters,
H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
May 1991, Biochemical and biophysical research communications,
H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
June 1993, Hypertension (Dallas, Tex. : 1979),
H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
January 1995, Journal of cardiovascular pharmacology,
H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
January 1995, Annual review of pharmacology and toxicology,
H Satoh, and K Tsukamoto, and Y Hashimoto, and N Hashimoto, and M Togo, and M Hara, and H Maekawa, and N Isoo, and S Kimura, and T Watanabe
January 1992, Agents and actions. Supplements,
Copied contents to your clipboard!